Medical Affairs’ Role in Health Economics & Outcomes Research within Oncology

Development of strong HO capabilities within MA organizations requires increase in MA’s involvement with HO groups, development of field-based HO capabilities, customization of HO data according to stakeholders, and building real world data capabilities to generate and utilize HO information.

Best Practices, LLC undertook a study to help companies focused on oncology therapies find better ways to develop successful Health Outcomes groups. This research delivers current data and best practices from Medical Affairs leaders with an oncology focus at top biopharmaceutical companies.

Study Snapshot

This study engaged 10 executives from leading life sciences companies. The analysis is focused on companies with oncology therapies.

Key Findings

· Longevity of HO Groups: HO programs are common, but they represent a young initiative for many of the benchmark class; sixty percent of companies have had it in place for less than three years.
· Reporting Structure: 60% of companies’ HO groups report to Medical Affairs. A majority of the interviewed executives think that HO groups must report to a science and research oriented department such as clinical or medical affairs. Between these two, medical affairs provides better opportunities for needs assessment, communicating HO data insights, and interacting with key decision makers.

Table of Contents

§ Executive Summary pp. 3-9

ü Research Objectives & Methodology pp. 3
ü Participating Companies pp. 4
ü Abbreviations pp. 5-6
ü Key Findings & Insights pp. 7-9